Subscribe

ASH 2015 - Castleman’s Disease, Lymphoma, and CLL

Stilgenbauer and colleagues reported on the impact of baseline genetic features and prognostic factors on efficacy and survival outcomes in the phase 2 RESONATE-17 study (PCYC-1117) that evaluated the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) harboring the deletion 17p (del17p) cytogenetic abnormality.
Preliminary results of a phase 2 trial of the selective inhibitor of spleen tyrosine kinase (Syk) entospletinib in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) were reported.
The results of a phase 3, randomized, placebo-controlled study that evaluated the PI3K-delta inhibitor idelalisib in combination with standard bendamustine/rituximab (BR) versus BR alone in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) were reported.
Researchers presented preliminary results of a randomized, phase 2 (PYRAMID) study that evaluated the efficacy and safety of frontline R-CHOP versus VR-CHOP in patients with the non-germinal center B-cell–like (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL).
Ujjaini and colleagues reported findings of a phase 1 study evaluating the triplet combination of the Bruton’s tyrosine kinase inhibitor ibrutinib plus rituximab and lenalidomide as a frontline regimen in patients with follicular lymphoma.
Researchers presented interim results of the CLL2-BIG trial that evaluated the anti-CD20 monoclonal antibody obinutuzumab plus the Bruton’s tyrosine kinase inhibitor ibrutinib following debulking with bendamustine in patients with high tumor burden to reduce the risk of severe infusion-related reactions (IRRs) in patients with chronic lymphocytic leukemia and high tumor burden.
Tedeschi and colleagues presented results of the head-to-head efficacy and safety comparison of the Bruton’s tyrosine kinase inhibitor ibrutinib versus chlorambucil treatment in the randomized, phase 3 RESONATE-2 trial of treatment-naïve patients ≥65 years of age with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL).
Subgroup analysis is presented of previously untreated patients in the ongoing, nonrandomized, multicohort phase 3b GREEN study that is evaluating the novel anti-CD20 monoclonal antibody obinutuzumab plus bendamustine treatment in patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL).
Researchers presented results of an open-label phase 2 trial (PCYC-1125-CA) that evaluated the Bruton’s tyrosine kinase inhibitor ibrutinib plus rituximab combination therapy in treatment-naïve patients with follicular lymphoma.
Safety and efficacy results of the randomized phase 3 RAY (MCL3001) study that compared Bruton’s tyrosine kinase inhibitor ibrutinib versus temsirolimus in patients with relapsed and/or refractory mantle-cell lymphoma (MCL) were reported.
Page 1 of 2
Results 1 - 10 of 20
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology